Intranasal Ketamine Treatment in an Adult With Autism Spectrum Disorder

Article Abstract †‹Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text. Ketamine, a noncompetitive antagonist at the N-methyl-d-aspartate glutamate receptor, has been demonstrated in controlled clinical trials to rapidly decrease symptoms of depression in adults via intravenous infusion and has demonstrated promising results in an uncontrolled trial of intranasal infusion in adolescents with bipolar disorder. Other glutamatergic modulators, including d-cycloserine, amantadine, and memantine, have been the focus of drug development targeting core social impairment in autism spectrum disorder (ASD). However, to date, there have been no reports of ketamine treatment in individuals with ASD.